Microbiota-dependent regulation of costimulatory and coinhibitory pathways via innate immune sensors and implications for immunotherapy

참고문헌 (152)

1. Durack, J., "The gut microbiome : relationships with disease and opportunities for therapy", J. Exp. Med, 216, pp.20~40 (2019)
2. Macpherson, A. J., "Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria", Science, 303, pp.1662~1665 (2004)
3. Gury-BenAri, M., "The spectrum and regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome", Cell, 166, pp.1231~1246 (2016)
4. Bouladoux, N., "The mouse model of infection with Citrobacter rodentium", Curr. Protoc. Immunol, 119, pp.19 15 11~19 15 25 (2017)
5. Geva-Zatorsky, N., "Mining the human gut microbiota for immunomodulatory organisms", Cell, 168, pp.928~943 (2017)
6. Sefik, E., "MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells", Science, 349, pp.993~997 (2015)
7. Kang, B., "Commensal microbiota drive the functional diversification of colon macrophages", Mucosal Immunol, 13, pp.216~229 (2020)
8. Lecuyer, E., "Segmented filamentous bacterium uses secondary and tertiary lymphoid tissues to induce gut IgA and specific T helper 17 cell responses", Immunity, 40, pp.608~620 (2014)
9. Chung, H., "Gut immune maturation depends on colonization with a hostspecific microbiota", Cell, 149, pp.1578~1593 (2012)
10. Rivollier, A., "Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon", J. Exp. Med, 209, pp.139~155 (2012)
11. Mager, L. F., "Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy", Science, 369, pp.1481~1489 (2020)
12. Rakoff-Nahoum, S., "Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis", Cell, 118, pp.229~241 (2004)
13. Rooks, M. G., "Gut microbiota, metabolites and host immunity", Nat. Rev. Immunol, 16, pp.341~352 (2016)
14. Britanova, L., "Interplay of innate lymphoid cells and the microbiota", Immunol. Rev, 279, pp.36~51 (2017)
15. Seo, G. Y., "The role of innate lymphoid cells in response to microbes at mucosal surfaces", Mucosal Immunol, 13, pp.399~412 (2020)
16. Artis, D., "The biology of innate lymphoid cells", Nature, 517, pp.293~301 (2015)
17. Longman, R. S., "CX(3)CR1(+)mononuclear phagocytes support colitisassociated innate lymphoid cell production of IL-22", J. Exp. Med, 211, pp.1571~1583 (2014)
18. Sano, T., "An IL-23R", IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses, 2015, pp.163, 381~393
19. Mortha, A., "Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis", Science, 343, pp.1249288~ (2014)
20. Zelante, T., "Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22", Immunity, 39, pp.372~385 (2013)
21. Talbot, J., "Feeding-dependent VIP neuron-ILC3 circuit regulates the intestinal barrier", Nature, 579, pp.575~580 (2020)
22. Howitt, M. R., "Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut", Science, 351, pp.1329~1333 (2016)
23. Nadjsombati, M. S., "Detection of succinate by intestinal tuft cells triggers a Type 2 innate immune circuit", Immunity, 49, pp.33~41 (2018)
24. Song, X., "Microbial bile acid metabolites modulate gut RORgamma(+)regulatory T cell homeostasis", Nature, 577, pp.410~415 (2020)
25. Hang, S., "Bile acid metabolites control T(H)17 and T(reg)cell differentiation", Nature, 576, pp.143~148 (2019)
26. Sipe, L. M., "Microbiome, bile acids, and obesity : How microbially modified metabolites shape anti-tumor immunity", Immunol. Rev, 295, pp.220~239 (2020)
27. Wexler, A. G., "An insider’s perspective : bacteroides as a window into the microbiome", Nat. Microbiol, 2, pp.17026~ (2017)
28. Stewart, C. J., "Temporal development of the gut microbiome in early childhood from the TEDDY study", Nature, 562, pp.583~588 (2018)
29. Erturk-Hasdemir, D., "Symbionts exploit complex signaling to educate the immune system", Proc. Natl Acad. Sci. USA, 116, pp.26157~26166 (2019)
30. Ochoa-Reparaz, J., "A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease", Mucosal Immunol, 3, pp.487~495 (2010)
31. Mazmanian, S. K., "A microbial symbiosis factor prevents intestinal inflammatory disease", Nature, 453, pp.620~625 (2008)
32. Stefan, K. L., "Commensal microbiota modulation of natural resistance to virus infection", Cell, 183, pp.1312~1324 (2020)
33. An, D., "Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells", Cell, 156, pp.123~133 (2014)
34. Savage, P. B., "Glycolipids for natural killer T cells", Chem. Soc. Rev, 35, pp.771~779 (2006)
35. Wieland Brown, L. C., "Production of alpha-galactosylceramide by a prominent member of the human gut microbiota", PLoS Biol, 11, pp.e1001610~ (2013)
36. Oh, S. F., "Host immunomodulatory lipids created by symbionts from dietary amino acids", Nature, 600, pp.302~307 (2021)
37. Blander, J. M., "Beyond pattern recognition : five immune checkpoints for scaling the microbial threat", Nat. Rev. Immunol, 12, pp.215~225 (2012)
38. Zhou, K., "Strategies to promote abundance of Akkermansia muciniphila, an emerging probiotics in the gut, evidence from dietary intervention studies", J. Funct. Foods, 33, pp.194~201 (2017)
39. Routy, B., "Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors", Science, 359, pp.91~97 (2018)
40. Bae, M., "Akkermansia muciniphila phospholipid induces homeostatic immune responses", Nature, 608, pp.168~173 (2022)
41. Ivanov, I. I., "Induction of intestinal Th17 cells by segmented filamentous bacteria", Cell, 139, pp.485~498 (2009)
42. Flannigan, K. L., "Segmented filamentous bacteria-induced immune responses: a balancing act between host protection and autoimmunity", Immunology, 154, pp.537~546 (2018)
43. Goto, Y., "Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation", Immunity, 40, pp.594~607 (2014)
44. Mitchison, N. A., "The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation", Eur. J. Immunol, 1, pp.18~27 (1971)
45. Mueller, D. L., "Clonal expansion versus functional clonal inactivation : a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy", Annu. Rev. Immunol, 7, pp.445~480 (1989)
46. Baumeister, S. H., "Coinhibitory pathways in immunotherapy for cancer", Annu. Rev. Immunol, 34, pp.539~573 (2016)
47. Chen, L., "Molecular mechanisms of T cell co-stimulation and coinhibition", Nat. Rev. Immunol, 13, pp.227~242 (2013)
48. Sharpe, A. H, "The B7-CD28 superfamily", Nat. Rev. Immunol, 2, pp.116~126 (2002)
49. Collins, M., "The B7 family of immune-regulatory ligands", Genome Biol, 6, pp.223~ (2005)
50. van der Merwe, P. A., "CD80(B7-1)binds both CD28 and CTLA-4 with a low affinity and very fast kinetics", J. Exp. Med, 185, pp.393~403 (1997)
51. Collins, A. V., "The interaction properties of costimulatory molecules revisited", Immunity, 17, pp.201~210 (2002)
52. Yoshinaga, S. K., "T-cell co-stimulation through B7RP-1 and ICOS", Nature, 402, pp.827~832 (1999)
53. Latchman, Y., "PD-L2 is a second ligand for PD-1 and inhibits T cell activation", Nat. Immunol, 2, pp.261~268 (2001)
54. Chaudhri, A., "PD-L1 binds to B7-1 only In Cis on the same cell surface", Cancer Immunol. Res, 6, pp.921~929 (2018)
55. Xiao, Y., "RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance", J. Exp. Med, 211, pp.943~959 (2014)
56. Zang, X., "Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas", Mod Pathol, 23, pp.1104~1112 (2010)
57. Zhong, X., "PD-L2 expression extends beyond dendritic cells", macrophages to B1 cells enriched for V(H)11, Eur. J. Immunol, pp.2007, 37[DOI]
58. Sharpe, A. H., "Mechanisms of costimulation", Immunol. Rev, 229, pp.5~11 (2009)
59. Croft, M., "Co-stimulatory members of the TNFR family : keys to effective T-cell immunity", Nat. Rev. Immunol, 3, pp.609~620 (2003)
60. Valatas, V., "TL1A(TNFSF15)and DR3(TNFRSF25) : a costimulatory system of cytokines with diverse functions in gut mucosal immunity", Front Immunol, 10, pp.583~ (2019)
61. Elgueta, R., "Molecular mechanism and function of CD40", CD40L engagement in the immune system, 2009, pp.229, 152~172
62. Seo, G. Y., "Epithelial HVEM maintains intraepithelial T cell survival and contributes to host protection", Sci. Immunol, 7, pp.eabm6931~ (2022)
63. Ware, C. F., "Realigning the LIGHT signaling network to control dysregulated inflammation", J Exp Med, 219, pp.e20220236~ (2022)
64. Beier, K. C., "Master switches of T-cell activation and differentiation", Eur. Respir. J, 29, pp.804~812 (2007)
65. Pappu, B. P., "TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease", J. Exp. Med, 205, pp.1049~1062 (2008)
66. Cai, G, "The CD160, BTLA, LIGHT", HVEM pathway: a bidirectional switch regulating T-cell activation, 2009, pp.229, 244~258
67. Anderson, A. C., "Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation", Immunity, 44, pp.989~1004 (2016)
68. Chiang, E. Y., "TIGIT-CD226-PVR axis : advancing immune checkpoint blockade for cancer immunotherapy", J. Immunother. Cancer, 10, pp.e004711~ (2022)
69. Nakayama, M., "Tim-3 mediates phagocytosis of apoptotic cells and crosspresentation", Blood, 113, pp.3821~3830 (2009)
70. Dixon, K. O., "TIM-3 restrains anti-tumour immunity by regulating inflammasome activation", Nature, 595, pp.101~106 (2021)
71. Goldberg, M. V., "LAG-3 in cancer immunotherapy", Curr. Top. Microbiol. Immunol, 344, pp.269~278 (2011)
72. Wang, J., "Fibrinogen-like protein 1 Is a major immune inhibitory ligand of LAG-3", Cell, 176, pp.334~347 (2019)
73. Andrews, L. P., "Molecular pathways and mechanisms of LAG3 in cancer therapy", Clin. Cancer Res, 28, pp.5030~5039 (2022)
74. Kouo, T., "Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells", Cancer Immunol Res, 3, pp.412~423 (2015)
75. Xu, F., "LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses", Cancer Res, 74, pp.3418~3428 (2014)
76. Guy, C., "LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation", Nat. Immunol, 23, pp.757~767 (2022)
77. Medzhitov, R., "A human homologue of the Drosophila Toll protein signals activation of adaptive immunity", Nature, 388, pp.394~397 (1997)
78. Winzler, C., "Maturation stages of mouse dendritic cells in growth factordependent long-term cultures", J. Exp Med, 185, pp.317~328 (1997)
79. Sallusto, F., "Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment : downregulation by cytokines and bacterial products", J. Exp. Med, 182, pp.389~400 (1995)
80. Kawai, T., "Unresponsiveness of MyD88-deficient mice to endotoxin", Immunity, 11, pp.115~122 (1999)
81. Kaisho, T., "Endotoxin-induced maturation of MyD88-deficient dendritic cells", J. Immunol, 166, pp.5688~5694 (2001)
82. Michelsen, K. S., "The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2", J. Biol. Chem, 276, pp.25680~25686 (2001)
83. Zhou, Z., "Antagonism between MyD88-and TRIF-dependent signals in B7RP-1 up-regulation", Eur. J. Immunol, 35, pp.1918~1927 (2005)
84. Gao, Y., "TLR2 directing PD-L2 expression inhibit T cells response in Schistosoma japonicum infection", PLoS ONE, 8, pp.e82480~ (2013)
85. Smith, P., "Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages", J. Immunol, 173, pp.1240~1248 (2004)
86. van der Kleij, D., "A novel host-parasite lipid cross-talk. Schistosomal lysophosphatidylserine activates toll-like receptor 2 and affects immune polarization", J. Biol. Chem, 277, pp.48122~48129 (2002)
87. Mann, J. E., "Microbe-mediated activation of toll-like receptor 2 drives PDL1expression in HNSCC", Cancers(Basel), 13, pp.4782~ (2021)
88. Beswick, E. J., "TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells", J. Immunol, 193, pp.2218~2229 (2014)
89. Yoon, B. R., "Preferential induction of the T cell auxiliary signaling molecule B7-H3 on synovial monocytes in rheumatoid arthritis", J. Biol. Chem, 291, pp.4048~4057 (2016)
90. Pawar, R. D., "B7x", B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis, 2015, pp.179, 329~343
91. Bullock, T. N., "Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells", J. Immunol, 174, pp.710~717 (2005)
92. Sinsuk Han, "Modulation of TNFSF expression in lymphoid tissue inducer cells by dendritic cells activated with Toll-like receptor ligands", BMB Reports, 44(2), pp.129~134 (2011), 생화학분자생물학회
93. Tone, M., "Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells", Proc. Natl Acad. Sci. USA, 100, pp.15059~15064 (2003)
94. Satake, Y., "Characterization of rat OX40 ligand by monoclonal antibody", Biochem. Biophys. Res. Commun, 270, pp.1041~1048 (2000)
95. Han, P., "An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection", J. Immunol, 172, pp.5931~5939 (2004)
96. Kamran, N., "Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells", PLoS ONE, 8, pp.e54406~ (2013)
97. Yang, X., "T cell Ig mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response", J. Immunol, 190, pp.2068~2079 (2013)
98. Steelman, A. J., "Astrocyte galectin-9 potentiates microglial TNF secretion", J. Neuroinflammation, 11, pp.144~ (2014)
99. Komai-Koma, M., "TLR2 is expressed on activated T cells as a costimulatory receptor", Proc. Natl Acad. Sci. USA, 101, pp.3029~3034 (2004)
100. Joseph, A. M., "Cross-talk between 4-1BB and TLR1-TLR2 signaling in CD8+ T cells regulates TLR2’s costimulatory effects", Cancer Immunol. Res, 4, pp.708~716 (2016)
101. Salerno, F., "Costimulation through TLR2 drives polyfunctional CD8(+)T cell Rresponses", J. Immunol, 202, pp.714~723 (2019)
102. Girardin, S. E., "Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan", Science, 300, pp.1584~1587 (2003)
103. Chamaillard, M., "An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid", Nat. Immunol, 4, pp.702~707 (2003)
104. Caruso, R., "NOD1 and NOD2 : signaling, host defense, and inflammatory disease", Immunity, 41, pp.898~908 (2014)
105. Hedl, M., "Pattern recognition receptor signaling in human dendritic cells is enhanced by ICOS ligand and modulated by the Crohn’s disease ICOSLG risk allele", Immunity, 40, pp.734~746 (2014)
106. Hewitt, R. E., "Immuno-inhibitory PD-L1 can be induced by a peptidoglycan", NOD2 mediated pathway in primary monocytic cells and is deficient in Crohn’s patients with homozygous NOD2 mutations, 2012, pp.143, 162~169
107. Asano, J., "Nucleotide oligomerization binding domain-like receptor signaling enhances dendritic cell-mediated cross-priming in vivo", J. Immunol, 184, pp.736~745 (2010)
108. Wagner, C. S., "TLR and nucleotide-binding oligomerization domain-like receptor signals differentially regulate exogenous antigen presentation", J. Immunol, 188, pp.686~693 (2012)
109. Schneider, M., "The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB", Nat. Immunol, 13, pp.823~831 (2012)
110. Zaki, M. H., "The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis", Cancer Cell, 20, pp.649~660 (2011)
111. Anand, P. K., "NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens", Nature, 488, pp.389~393 (2012)
112. Xia, X., "NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK", Immunity, 34, pp.843~853 (2011)
113. Kanneganti, T. D., "Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin", Nalp3, 2006, pp.440, 233~236
114. Lu, F., "NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma", Cancer Lett, 497, pp.178~189 (2021)
115. Fu, A., "Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer", Cell, 185, pp.1356~1372 (2022)
116. Galeano Nino, J. L., "Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer", Nature, 611, pp.810~817 (2022)
117. Nejman, D., "The human tumor microbiome is composed of tumor typespecific intracellular bacteria", Science, 368, pp.973~980 (2020)
118. Sonnenberg, G. F., "Functional interactions between innate lymphoid cells and adaptive immunity", Nat. Rev. Immunol, 19, pp.599~613 (2019)
119. von Burg, N., "Activated group 3 innate lymphoid cells promote T-cellmediated immune responses", Proc. Natl Acad. Sci. USA, 111, pp.12835~12840 (2014)
120. Lehmann, F. M., "Microbiota-induced tissue signals regulate ILC3-mediated antigen presentation", Nat. Commun, 11, pp.1794~ (2020)
121. Hepworth, M. R., "Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4(+) T cells", Science, 348, pp.1031~1035 (2015)
122. Schwartz, C., "ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control", J. Exp. Med, 214, pp.2507~2521 (2017)
123. Halim, T. Y. F., "Tissue-restricted adaptive type 2 immunity is orchestrated by expression of the costimulatory molecule OX40L on Group 2 innate lymphoid cells", Immunity, 48, pp.1195~1207 (2018)
124. De Salvo, C., "NOD2 drives early IL-33-dependent expansion of group 2innate lymphoid cells during Crohn’s disease-like ileitis", J. Clin. Invest, 131, pp.e140624~ (2021)
125. Castellanos, J. G., "Microbiota-induced TNF-like ligand 1A drives Group 3innate lymphoid cell-mediated barrier protection and intestinal T cell activation during Colitis", Immunity, 49, pp.1077~1089 (2018)
126. Maazi, H., "ICOS : ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity", Immunity, 42, pp.538~551 (2015)
127. Seo, G. Y., "LIGHT-HVEM signaling in innate lymphoid cell subsets protects against enteric bacterial infection", Cell Host Microbe, 24, pp.249~260 (2018)
128. Taylor, S., "PD-1 regulates KLRG1(+)group 2 innate lymphoid cells", J. Exp. Med, 214, pp.1663~1678 (2017)
129. Helou, D. G., "PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity", Nat. Commun, 11, pp.3998~ (2020)
130. Hurrell, B. P., "TNFR2 signaling enhances ILC2 survival, function, and induction of airway hyperreactivity", Cell Rep, 29, pp.4509~4524 (2019)
131. Galle-Treger, L., "Costimulation of type-2 innate lymphoid cells by GITR promotes effector function and ameliorates type 2 diabetes", Nat. Commun, 10, pp.713~ (2019)
132. Crellin, N. K., "Regulation of cytokine secretion in human CD127(+)LTi-like innate lymphoid cells by Toll-like receptor 2", Immunity, 33, pp.752~764 (2010)
133. Martinez, J., "Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection", PLoS Pathog, 6, pp.e1000811~ (2010)
134. Ishii, T., "Activation through toll-like receptor 2 on group 2 innate lymphoid cells can induce asthmatic characteristics", Clin. Exp. Allergy, 49, pp.1624~1632 (2019)
135. Xu, H., "Type 3 innate lymphoid cell depletion is mediated by TLRs in lymphoid tissues of simian immunodeficiency virus-infected macaques", FASEB J, 29, pp.5072~5080 (2015)
136. Zang, X., "The B7 family and cancer therapy : costimulation and coinhibition", Clin. Cancer Res, 13, pp.5271~5279 (2007)
137. Gopalakrishnan, V., "Gut microbiome modulates response to anti-PD-1immunotherapy in melanoma patients", Science, 359, pp.97~103 (2018)
138. Matson, V., "The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients", Science, 359, pp.104~108 (2018)
139. Tanoue, T., "A defined commensal consortium elicits CD8 T cells and anticancer immunity", Nature, 565, pp.600~605 (2019)
140. Davar, D., "Fecal microbiota transplant overcomes resistance to anti-PD-1therapy in melanoma patients", Science, 371, pp.595~602 (2021)
141. Baruch, E. N., "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients", Science, 371, pp.602~609 (2021)
142. Griffin, M. E., "Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy", Science, 373, pp.1040~1046 (2021)
143. Lam, K. C., "Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment", Cell, 184, pp.5338~5356 (2021)
144. Park, J. S., "Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance", Nature, 617, pp.377~385 (2023)
145. Curran, M. A., "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors", Proc. Natl Acad. Sci. USA, 107, pp.4275~4280 (2010)
146. McCulloch, J. A., "Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1", Nat. Med, 28, pp.545~556 (2022)
147. Wang, Y., "Microbiome influencers of checkpoint blockade-associated toxicity", J. Exp. Med, 220, pp.e20220948~ (2023)
148. Postow, M. A., "Immune-related adverse events associated with immune checkpoint blockade", N. Engl. J. Med, 378, pp.158~168 (2018)
149. Andrews, M. C., "Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade", Nat. Med, 27, pp.1432~1441 (2021)
150. Dubin, K., "Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis", Nat. Commun, 7, pp.10391~ (2016)
151. Hu, Z. I., "Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota", Proc. Natl Acad. Sci. USA, 119, pp.e2200348119~ (2022)
152. Wang, Y., "Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis", Nat. Med, 24, pp.1804~1808 (2018)

관련 논문AI추천